Cargando…

Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes

BACKGROUND/AIM: To assess visual acuity (VA) outcomes and antivascular endothelial growth factor (anti-VEGF) treatment intensity in diabetic macular oedema (DMO). METHODS: Retrospective analysis was performed in treatment-naïve patients with DMO from 2013 to 2018 using a database of aggregated de-id...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciulla, Thomas A, Pollack, John S, Williams, David F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848066/ https://www.ncbi.nlm.nih.gov/pubmed/32265201 http://dx.doi.org/10.1136/bjophthalmol-2020-315933

Ejemplares similares

Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes
por: Ciulla, Thomas, et al.
Publicado: (2021)

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2021)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti-VEGF
por: Zou, Di, et al.
Publicado: (2021)

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
por: Sadda, Srinivas R., et al.
Publicado: (2019)

Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema
por: Kozak, Igor, et al.
Publicado: (2023)

Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study
por: Shimura, Masahiko, et al.
Publicado: (2020)

Prediction of Visual Acuity after anti-VEGF Therapy in Diabetic Macular Edema by Machine Learning
por: Zhang, Ying, et al.
Publicado: (2022)

Indicators of Visual Prognosis in Diabetic Macular Oedema
por: Sen, Sagnik, et al.
Publicado: (2021)

Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result
por: Lip, P L, et al.
Publicado: (2018)

Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
por: Sam-Oyerinde, Olapeju A., et al.
Publicado: (2023)

Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review
por: Wang, Patrick, et al.
Publicado: (2022)

Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study
por: Busch, Catharina, et al.
Publicado: (2019)

Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
por: Kern, Christoph, et al.
Publicado: (2020)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy, Balaji, et al.
Publicado: (2020)

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema
por: Abdel-Hay, Ahmed, et al.
Publicado: (2018)

Aflibercept in clinical practice; visual acuity, injection numbers and adherence to treatment, for diabetic macular oedema in 21 UK hospitals over 3 years
por: Talks, S. J., et al.
Publicado: (2021)

Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema
por: Andrade Romo, Jorge S., et al.
Publicado: (2018)

Randomised clinical trial evaluating best-corrected visual acuity and central macular thickness after 532-nm subthreshold laser grid photocoagulation treatment in diabetic macular oedema
por: Pei-pei, W, et al.
Publicado: (2015)

VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017)

Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy
por: Mikhail, Michael, et al.
Publicado: (2018)

Visual outcomes of observation, macular laser and anti-VEGF in diabetic macular edema in type 1 diabetes: a real-world study
por: Wirkkala, Joonas, et al.
Publicado: (2022)

Functional Visual Acuity in Age-Related Macular Degeneration
por: Tomita, Yohei, et al.
Publicado: (2016)

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)

Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland
por: Zirpel, Johanna J., et al.
Publicado: (2021)

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
por: Karttunen, Tommi, et al.
Publicado: (2019)

THE VISUAL ACUITY AND INTENSITY DISCRIMINATION OF DROSOPHILA
por: Hecht, Selig, et al.
Publicado: (1934)

Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease
por: Gale, R, et al.
Publicado: (2017)

Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
por: Granstam, Elisabet, et al.
Publicado: (2021)

The evolutionary history of 2,658 cancers
por: Gerstung, Moritz, et al.
Publicado: (2020)

A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea
por: Kim, Jae Hui, et al.
Publicado: (2022)

Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study
por: Shimura, Masahiko, et al.
Publicado: (2020)

Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023)

Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: A post hoc analysis of PEACHTREE
por: Singer, Michael A., et al.
Publicado: (2021)

Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy
por: Eraslan, Seher, et al.
Publicado: (2020)

Effect of macular photocoagulation on visual acuity of Omani patients with clinically significant macular edema
por: Zaidi, Zafar A., et al.
Publicado: (2009)

Change in choroidal volume after dexamethasone intravitreal implant in eyes with diabetic macular oedema
por: Posch‐Pertl, Laura, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6jeq6a6prj1a1ghmo2ekfmevc6